Strong Support
descriptive
Over six months of monitoring, no one in the study who received the recombinant zoster vaccine had a life-threatening reaction, autoimmune condition, or died as a result of the vaccine.
73
0
Evidence from Studies
Supporting (1)
73
Community contributions welcome
73
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
Randomized Controlled Trial
Human
2025 Mar 19Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.